Literature DB >> 26551677

Ebola viral load at diagnosis associates with patient outcome and outbreak evolution.

Marc-Antoine de La Vega, Grazia Caleo, Jonathan Audet, Xiangguo Qiu, Robert A Kozak, James I Brooks, Steven Kern, Anja Wolz, Armand Sprecher, Jane Greig, Kamalini Lokuge, David K Kargbo, Brima Kargbo, Antonino Di Caro, Allen Grolla, Darwyn Kobasa, James E Strong, Giuseppe Ippolito, Michel Van Herp, Gary P Kobinger.   

Abstract

BACKGROUND: Ebola virus (EBOV) causes periodic outbreaks of life-threatening EBOV disease in Africa. Historically, these outbreaks have been relatively small and geographically contained; however, the magnitude of the EBOV outbreak that began in 2014 in West Africa has been unprecedented. The aim of this study was to describe the viral kinetics of EBOV during this outbreak and identify factors that contribute to outbreak progression.
METHODS: From July to December 2014, one laboratory in Sierra Leone processed over 2,700 patient samples for EBOV detection by quantitative PCR (qPCR). Viremia was measured following patient admission. Age, sex, and approximate time of symptom onset were also recorded for each patient. The data was analyzed using various mathematical models to find trends of potential interest.
RESULTS: The analysis revealed a significant difference (P = 2.7 × 10(-77)) between the initial viremia of survivors (4.02 log10 genome equivalents [GEQ]/ml) and nonsurvivors (6.18 log10 GEQ/ml). At the population level, patient viral loads were higher on average in July than in November, even when accounting for outcome and time since onset of symptoms. This decrease in viral loads temporally correlated with an increase in circulating EBOV-specific IgG antibodies among individuals who were suspected of being infected but shown to be negative for the virus by PCR.
CONCLUSIONS: Our results indicate that initial viremia is associated with outcome of the individual and outbreak duration; therefore, care must be taken in planning clinical trials and interventions. Additional research in virus adaptation and the impacts of host factors on EBOV transmission and pathogenesis is needed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26551677      PMCID: PMC4665775          DOI: 10.1172/JCI83162

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone.

Authors:  Yi-Gang Tong; Wei-Feng Shi; Di Liu; Jun Qian; Long Liang; Xiao-Chen Bo; Jun Liu; Hong-Guang Ren; Hang Fan; Ming Ni; Yang Sun; Yuan Jin; Yue Teng; Zhen Li; David Kargbo; Foday Dafae; Alex Kanu; Cheng-Chao Chen; Zhi-Heng Lan; Hui Jiang; Yang Luo; Hui-Jun Lu; Xiao-Guang Zhang; Fan Yang; Yi Hu; Yu-Xi Cao; Yong-Qiang Deng; Hao-Xiang Su; Yu Sun; Wen-Sen Liu; Zhuang Wang; Cheng-Yu Wang; Zhao-Yang Bu; Zhen-Dong Guo; Liu-Bo Zhang; Wei-Min Nie; Chang-Qing Bai; Chun-Hua Sun; Xiao-Ping An; Pei-Song Xu; Xiang-Li-Lan Zhang; Yong Huang; Zhi-Qiang Mi; Dong Yu; Hong-Wu Yao; Yong Feng; Zhi-Ping Xia; Xue-Xing Zheng; Song-Tao Yang; Bing Lu; Jia-Fu Jiang; Brima Kargbo; Fu-Chu He; George F Gao; Wu-Chun Cao
Journal:  Nature       Date:  2015-05-13       Impact factor: 49.962

2.  Use of bacteriophage MS2 as an internal control in viral reverse transcription-PCR assays.

Authors:  Jens Dreier; Melanie Störmer; Knut Kleesiek
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Early diagnosis of Lassa fever by reverse transcription-PCR.

Authors:  A H Demby; J Chamberlain; D W Brown; C S Clegg
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

4.  Enhanced detection of Rift Valley fever virus using molecular assays on whole blood samples.

Authors:  Allen Grolla; Masfique Mehedi; Robbin Lindsay; Catharine Bosio; Adriano Duse; Heinz Feldmann
Journal:  J Clin Virol       Date:  2012-05-24       Impact factor: 3.168

Review 5.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

6.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

7.  High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.

Authors:  Pierre Becquart; Nadia Wauquier; Tanel Mahlakõiv; Dieudonné Nkoghe; Cindy Padilla; Marc Souris; Benjamin Ollomo; Jean-Paul Gonzalez; Xavier De Lamballerie; Mirdad Kazanji; Eric M Leroy
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

8.  Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome.

Authors:  Jonathan S Towner; Pierre E Rollin; Daniel G Bausch; Anthony Sanchez; Sharon M Crary; Martin Vincent; William F Lee; Christina F Spiropoulou; Thomas G Ksiazek; Mathew Lukwiya; Felix Kaducu; Robert Downing; Stuart T Nichol
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Ebolavirus is evolving but not changing: No evidence for functional change in EBOV from 1976 to the 2014 outbreak.

Authors:  Abayomi S Olabode; Xiaowei Jiang; David L Robertson; Simon C Lovell
Journal:  Virology       Date:  2015-04-14       Impact factor: 3.616

10.  Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Authors:  Jens H Kuhn; Kristian G Andersen; Yīmíng Bào; Sina Bavari; Stephan Becker; Richard S Bennett; Nicholas H Bergman; Olga Blinkova; Steven Bradfute; J Rodney Brister; Alexander Bukreyev; Kartik Chandran; Alexander A Chepurnov; Robert A Davey; Ralf G Dietzgen; Norman A Doggett; Olga Dolnik; John M Dye; Sven Enterlein; Paul W Fenimore; Pierre Formenty; Alexander N Freiberg; Robert F Garry; Nicole L Garza; Stephen K Gire; Jean-Paul Gonzalez; Anthony Griffiths; Christian T Happi; Lisa E Hensley; Andrew S Herbert; Michael C Hevey; Thomas Hoenen; Anna N Honko; Georgy M Ignatyev; Peter B Jahrling; Joshua C Johnson; Karl M Johnson; Jason Kindrachuk; Hans-Dieter Klenk; Gary Kobinger; Tadeusz J Kochel; Matthew G Lackemeyer; Daniel F Lackner; Eric M Leroy; Mark S Lever; Elke Mühlberger; Sergey V Netesov; Gene G Olinger; Sunday A Omilabu; Gustavo Palacios; Rekha G Panchal; Daniel J Park; Jean L Patterson; Janusz T Paweska; Clarence J Peters; James Pettitt; Louise Pitt; Sheli R Radoshitzky; Elena I Ryabchikova; Erica Ollmann Saphire; Pardis C Sabeti; Rachel Sealfon; Aleksandr M Shestopalov; Sophie J Smither; Nancy J Sullivan; Robert Swanepoel; Ayato Takada; Jonathan S Towner; Guido van der Groen; Viktor E Volchkov; Valentina A Volchkova; Victoria Wahl-Jensen; Travis K Warren; Kelly L Warfield; Manfred Weidmann; Stuart T Nichol
Journal:  Viruses       Date:  2014-09-26       Impact factor: 5.048

View more
  64 in total

1.  Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Authors:  John C Kash; Kathie-Anne Walters; Jason Kindrachuk; David Baxter; Kelsey Scherler; Krisztina B Janosko; Rick D Adams; Andrew S Herbert; Rebekah M James; Spencer W Stonier; Matthew J Memoli; John M Dye; Richard T Davey; Daniel S Chertow; Jeffery K Taubenberger
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

2.  Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease.

Authors:  Jerry F Brown; John M Dye; Sam Tozay; Gertrude Jeh-Mulbah; David A Wohl; William A Fischer; Coleen K Cunningham; Kathleen Rowe; Peter Zacharias; James van Hasselt; David A Norwood; Nathan M Thielman; Samantha E Zak; David L Hoover
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

3.  Characterizing risk of Ebola transmission based on frequency and type of case-contact exposures.

Authors:  Laura A Skrip; Mosoka P Fallah; Stephen G Gaffney; Rami Yaari; Dan Yamin; Amit Huppert; Luke Bawo; Tolbert Nyenswah; Alison P Galvani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-05-26       Impact factor: 6.237

4.  Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples.

Authors:  Maiken W Rosenstierne; Christopher E Jensen; Anders Fomsgaard
Journal:  J Vis Exp       Date:  2018-06-30       Impact factor: 1.355

5.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

Authors:  Richard T Davey; Lori Dodd; Michael A Proschan; James Neaton; Jacquie Neuhaus Nordwall; Joseph S Koopmeiners; John Beigel; John Tierney; H Clifford Lane; Anthony S Fauci; Moses B F Massaquoi; Foday Sahr; Denis Malvy
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

6.  The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

Authors:  Richard T Davey; Lori Dodd; Michael Proschan; Peter Jahrling; Lisa Hensley; Elizabeth Higgs; H Clifford Lane
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

7.  Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Authors:  Matthew L Boisen; Robert W Cross; Jessica N Hartnett; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Sidiki Safa; Mbalu Fonnie; Francis Baimba; Veronica J Koroma; Joan B Geisbert; Stephanie McCormick; Diana K S Nelson; Molly M Millett; Darin Oottamasathien; Abby B Jones; Ha Pham; Bethany L Brown; Jeffrey G Shaffer; John S Schieffelin; Brima Kargbo; Momoh Gbetuwa; Sahr M Gevao; Russell B Wilson; Kelly R Pitts; Thomas W Geisbert; Luis M Branco; Sheik H Khan; Donald S Grant; Robert F Garry
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

8.  Ebola Virus Shedding and Transmission: Review of Current Evidence.

Authors:  Pauline Vetter; William A Fischer; Manuel Schibler; Michael Jacobs; Daniel G Bausch; Laurent Kaiser
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

9.  Rapid Bedside Inactivation of Ebola Virus for Safe Nucleic Acid Tests.

Authors:  Maiken Worsøe Rosenstierne; Helen Karlberg; Karoline Bragstad; Gunnel Lindegren; Malin Lundahl Stoltz; Cristiano Salata; Anne-Marte Bakken Kran; Susanne Gjeruldsen Dudman; Ali Mirazimi; Anders Fomsgaard
Journal:  J Clin Microbiol       Date:  2016-07-27       Impact factor: 5.948

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.